Trial site
MEDICUS SERVICES s.r.o.
Brandýs nad Labem, 250 01, CzechiaEU-13 widening countryNot linked to an institution yet
- 17running trials
- 6closed trials
The trials here
What the 23 trials at this site are about, from their registry records.
- Phase
- Phase 320 trials
- Phase 23 trials
- Status
- Recruiting10 trials
- Active, not recruiting6 trials
- Completed6 trials
- Not yet recruiting1 trial
- Lead sponsor
- AstraZeneca4 trials
- Boehringer Ingelheim3 trials
- Anthos Therapeutics, Inc.2 trials
- Ionis Pharmaceuticals, Inc.2 trials
- Kailera2 trials
- and 9 more
Running trials
Recruiting
A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure
NCT07584967· Phase 2· AnaCardio AB· Source
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
NCT07284901· Phase 3· Kailera· Source
Active, not recruiting
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
NCT07284875· Phase 3· Kailera· Source
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
2024-516654-22-00· Phase 3· Amgen Inc.· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· Phase 3· Boehringer Ingelheim· Source
Recruiting
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
NCT06929806· Phase 3· Pharmacosmos A/S· Source
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· Phase 3· AstraZeneca· Source
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200· Phase 3· Anthos Therapeutics, Inc.· Source
Active, not recruiting
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
NCT05681351· Phase 3· Ionis Pharmaceuticals, Inc.· Source
Active, not recruiting
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
NCT04755283· Phase 2· Anthos Therapeutics, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error